In a phase 2 trial of obese subjects, cagrilintide used in different subcutaneous doses once weekly was associated with a mean weight loss of 6-10.8% after 26 weeks, compared with 9.0% with the glucagon-like 1 receptor (GLP-1R) liraglutide (3 mg/d) and 3% with placebo at 26 weeks
Higher time in range with combined therapy In a second presentation, Chantal Mathieu, MD, PhD, professor of medicine and chair of endocrinology at the University Hospital Gasthuisberg Leuven in Belgium, presented CGM data from the trial
Key Research Areas for the Wolverine Stack Dual-phase tissue repair pathway studies vascular/ECM organisation (BPC-157) and cellular migration/cytoskeletal reconstruction (TB-500) Musculoskeletal healing pathway research tendon, ligament, muscle, and connective tissue models Angiogenesis studies VEGF/VEGFR2 upregulation, vascular tube formation, capillary network organisation Fibroblast migration, adhesion, and ECM stabilisation assays Stem/progenitor cell mobilisation and tissue-site differentiation studies Anti-inflammatory and anti-oxidative stress pathway research TNF-, IL-6, reactive oxygen species modulation Collagen synthesis, fibre alignment, and organisational quality studies Combination vs
European Journal of Endocrinology
over-the-counter (OTC) saline and decongestant sprays
